NCT06489600

Brief Summary

This is open-label, interventional, prospective, safety in-use tolerability study of test product "No Rays, Thanks Mineral Sunscreen" in healthy adult human subjects with dry and sensitive skin.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
27

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Dec 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 28, 2024

Completed
10 days until next milestone

First Posted

Study publicly available on registry

July 8, 2024

Completed
5 months until next milestone

Study Start

First participant enrolled

December 19, 2024

Completed
16 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 4, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 4, 2025

Completed
Last Updated

March 3, 2025

Status Verified

February 1, 2025

Enrollment Period

16 days

First QC Date

June 28, 2024

Last Update Submit

February 27, 2025

Conditions

Outcome Measures

Primary Outcomes (6)

  • Change in local intolerance assessment for skin irritation using 4-point scoring scale where 0 indicate absent and 3 indicate severe.

    To assess the safety of the test product in terms of change in local intolerance assessment for irritation by dermatological assessment

    On Day 01 at T15 minutes and on Day 15 (± 2 Days).

  • Change in local intolerance assessment for skin dryness using 4-point scoring scale where 0 indicate absent and 3 indicate severe.

    To assess the safety of the test product in terms of change in local intolerance assessment for dryness by dermatological assessment

    On Day 01 at T15 minutes and on Day 15 (± 2 Days).

  • Change in local intolerance assessment for skin oedema using 4-point scoring scale where 0 indicate absent and 3 indicate severe.

    To assess the safety of the test product in terms of change in local intolerance assessment for oedema by dermatological assessment

    On Day 01 at T15 minutes and on Day 15 (± 2 Days).

  • safety of the test product in terms of local intolerance assessment of irritation (Patient Global Assessment scale) where 0 indicate not at all and 10 indicate very severe.

    To evaluate the safety of the test product in terms of local intolerance assessment of irritation by Patient Global Assessment scale.

    On Day 01 at T15 minutes and on Day 15 (± 2 Days).

  • safety of the test product in terms of local intolerance assessment of dryness (Patient Global Assessment scale) where 0 indicate not at all and 10 indicate very severe.

    To evaluate the safety of the test product in terms of local intolerance assessment of dryness by Patient Global Assessment scale.

    On Day 01 at T15 minutes and on Day 15 (± 2 Days).

  • safety of the test product in terms of local intolerance assessment of oedema (Patient Global Assessment scale) where 0 indicate not at all and 10 indicate very severe.

    To evaluate the safety of the test product in terms of local intolerance assessment of oedema by Patient Global Assessment scale.

    On Day 01 at T15 minutes and on Day 15 (± 2 Days).

Secondary Outcomes (10)

  • where will you rank the test product in terms of appearance in which 1 indicate very poor and 5 indicate excellent.

    On Day 01 and after test product usage on Day 01 at T15 minutes, and on Day 15 (±2 Days)

  • where will you rank the test product in terms of spreadibility in which 1 indicate very poor and 5 indicate excellent.

    On Day 01 and after test product usage on Day 01 at T15 minutes, and on Day 15 (±2 Days)

  • where will you rank the test product in terms of texture in which 1 indicate very poor and 5 indicate excellent.

    On Day 01 and after test product usage on Day 01 at T15 minutes, and on Day 15 (±2 Days)

  • where will you rank the test product in terms of fragrance in which 1 indicate very poor and 5 indicate excellent.

    On Day 01 and after test product usage on Day 01 at T15 minutes, and on Day 15 (±2 Days)

  • where will you rank the test product in terms of absorption in which 1 indicate very poor and 5 indicate excellent.

    On Day 01 and after test product usage on Day 01 at T15 minutes, and on Day 15 (±2 Days)

  • +5 more secondary outcomes

Study Arms (1)

No Rays, Thanks Mineral sunscreen

EXPERIMENTAL

Wash your face with standard facewash and apply a pea size amount on the face in the morning.

Other: No Rays, Thanks Mineral sunscreen

Interventions

Wash your face with standard facewash and apply a pea size amount on the face in the morning. Dosage form: semi-solid frequency: Once in a day Route of Administration: Topical

No Rays, Thanks Mineral sunscreen

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Age: 18 to 55 years (both inclusive) at the time of consent.
  • Sex: Healthy male and non-pregnant/non-lactating females. (Preferably equal ratio of males and females)
  • Females of childbearing potential must have a self-reported negative pregnancy test.
  • Subject are generally in good health.
  • Subject with dry and sensitive skins. (As per the dermatological evaluation).
  • Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.
  • If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.
  • Subjects are willing to give written informed consent and are willing to come for regular follow up.
  • Subjects who commit not to use medicated skincare products other than the test product for the entire duration of the study.
  • Subject who have not participated in a similar investigation in the past three months.
  • Willing to use test product throughout the study period.

You may not qualify if:

  • History of any dermatological condition of the skin disease.
  • Subject with present condition of allergic response to any cosmetic product.
  • Subjects under chronic medication (e.g. aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy etc.) that might influence the outcome of the study.
  • History of alcohol or drug addiction.
  • The subject has clinically significant skin disease, which may contraindicate participation, including psoriasis, eczema, skin cancer or other skin pathology.
  • Subjects having skin infections like bacterial, fungal, viral infections.
  • The subject has skin irritation, open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the face that can interfere with the reading.
  • Be wearing any facial makeup, including false eyelashes, on the day of the study visit.
  • Subjects having hypersensitive skin.
  • Subjects using other marketed sun screen products during the study period.
  • Pregnant or breastfeeding or planning to become pregnant during the study period.
  • History of chronic illness which may influence the cutaneous state.
  • Subjects participating in other similar cosmetics, devices or therapeutic trials or skincare products within the last four weeks.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NovoBliss Research Pvt.Ltd

Ahmedabad, Gujarat, 382481, India

Location

Study Officials

  • Dr. Nayan K Patel

    NovoBliss Research Pvt Ltd

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Model Details: open-label, interventional, prospective, safety in-use tolerability
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 28, 2024

First Posted

July 8, 2024

Study Start

December 19, 2024

Primary Completion

January 4, 2025

Study Completion

January 4, 2025

Last Updated

March 3, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

Locations